BHWM
SNDX icon

Beaird Harris Wealth Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Beaird Harris Wealth Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62
Closed -$1.26K – 685
2024
Q2 		$1.26K Buy
+62
New +$1.3K ﹤0.01% 577

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beaird Harris Wealth Management's SNDX Position: Q3 2024 in Review

Beaird Harris Wealth Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 62 shares — an estimated $1.26K sold.

Beaird Harris Wealth Management first reported a position in SNDX in Q2 2024 and held it in 1 quarter. The position peaked at $1.26K in Q2 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • Beaird Harris Wealth Management reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 62 Syndax Pharmaceuticals shares in Q3 2024, an estimated $1.26K.
  • Beaird Harris Wealth Management first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Beaird Harris Wealth Management's Syndax Pharmaceuticals position peaked at $1.26K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Beaird Harris Wealth Management's 13F filing for Q3 2024, filed 2 Dec 2024.